Department of Radiology, Acibadem M.A.A. University School of Medicine, Atakent University Hospital, 34755, Istanbul, Turkey.
Acibadem M.A.A. University Senology Research Institute, 34457, Sarıyer, Istanbul, Turkey.
Eur Radiol. 2021 Mar;31(3):1718-1726. doi: 10.1007/s00330-020-07265-y. Epub 2020 Sep 16.
To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography.
In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings.
Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively.
In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade.
• All invasive cancer cases and 87.8% of all in situ cancer cases were detected with MRI, showing a low false-negative rate of 4.7%. • Dynamic contrast-enhanced MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are predominantly low-to-medium grade. • If a decision for biopsy were made based on MRI findings in mammography-detected microcalcifications in this study, biopsy would not be performed to 119 cases (26.8%).
探讨 MRI 对乳腺 X 线摄影可疑孤立微钙化的纳入评估作用。
在这项前瞻性多中心研究中,对筛查性乳腺 X 线摄影中发现孤立微钙化的病例进行动态对比增强 MRI(DCE-MRI)检查,将相关钙化定位的对比增强视为 MRI 的阳性发现。六位经验丰富的乳腺放射科医生评估图像并进行活检。记录影像学表现和组织病理学结果。计算乳腺 MRI 的灵敏度、特异度、NPV 和 PPV,并与组织病理学结果进行比较。
对 444 名女性的筛查性乳腺 X 线片检测到的可疑微钙化进行评估。其中 276 例(62.2%)诊断为良性,168 例(37.8%)为恶性。325 例(73.2%)病例的微钙化定位有对比增强。DCE-MRI 对 102 例浸润性癌和 58 例(87.9%)DCIS 均为阳性。DCE-MRI 对 8 例 DCIS 漏诊,其中 1 例为高级别,7 例为中低级别。DCE-MRI 的假阴性率为 4.76%。DCE-MRI 对乳腺 X 线摄影可疑微钙化的灵敏度、特异度、PPV 和 NPV 分别为 95.2%、40.2%、49.2%和 93.3%。
在这项研究中,所有浸润性癌和所有 DCIS (除 8 例[12.1%])均通过 DCE-MRI 检出。DCE-MRI 可用于决策算法,减少乳腺 X 线摄影可疑钙化的活检数量,同时也可能漏诊少数中低级别 DCIS 病例。
所有浸润性癌病例和 87.8%的原位癌病例均通过 MRI 检出,假阴性率低至 4.7%。
动态对比增强 MRI 可用于决策算法,减少乳腺 X 线摄影可疑钙化的活检数量,但可能会漏诊少数以中低级别为主的 DCIS 病例。
如果根据本研究中乳腺 X 线摄影发现的微钙化做出 MRI 检查的决策,那么有 119 例(26.8%)病例无需进行活检。